MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
iVascular
Not all DCBs are the same
New-generation coating technologies can influence safety and effectiveness.
By Prof. Ulf Teichgräber, MD, with expert opinion by Koen Deloose, MD
Sponsored by iVascular
Best DCB Outcomes: How Next-Generation Coating Technology Influences Clinical Effectiveness
By Prof. Ulf Teichgräber, MD; Prof. Vincent Riambau, MD, PhD; and Roberto Ferraresi, MD
Drug-Coated Balloon Update: Are All DCBs the Same?
A summary of presentations on the use of DCBs and treatment of complex lesions from the inaugural iVS.
With Fabrizio Fanelli, MD, EBIR; Prof. Ulf Teichgräber, MD; and Koen Deloose, MD
EffPac Clinical Trial of iVascular's Luminor 35 DCB Begins Enrollment
October 8, 2015—The first two cases in the EffPac randomized, clinical, multicenter trial of iVascular’s Luminor 35 drug-coated balloon (DCB) system were successfully performed by Principal Investigator Prof.
Two-Year Data Presented From EffPac Trial of iVascular's Luminor DCB
May 23, 2019—iVascular announced that the 24-month EffPac trial results were presented by Professor Ulf Teichgräber, MD, at EuroPCR held May 21–24 in Paris, France.
EffPac and TINTIN Data Presented for iVascular’s Luminor DCB in Complex Femoropopliteal Lesions
February 4, 2021–Clinical evidence of iVascular’s Luminor drug-coated balloon (DCB) in complex lesions with long-term follow-up data were presented at LINC 2021, the Leipzig Interventional Course held virtually on January 25-29.
Concept Medical’s MagicTouch PTA in Femoropopliteal Disease Evaluated at 3 Years in SIRONA Trial
April 29, 2026—Concept Medical Inc. announced preliminary 3-year follow-up data from the SIRONA randomized trial comparing the company’s MagicTouch PTA device, a sirolimus-coated balloon for percutaneous transluminal angioplasty (PTA), versus paclitaxel-coated balloon angioplasty in femoropopliteal artery disease.
Efficacy Data Presented for iVascular's Luminor DCB
September 18, 2017—iVascular SLU announced that the efficacy of the company's Luminor drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD) was demonstrated in data presented at CIRSE 2017, the annual congress of the Cardiovascular and Interventional Radiological Society of Europe, held September 16–20 in Copenhagen, Denmark.
Concept Medical’s MagicTouch Sirolimus-Coated PTA Balloon Evaluated in LIMES Trial for CLTI BTK Interventions
July 29, 2022—Concept Medical Inc. announced the initiation of LIMES trial, which has enrolled 15 patients to evaluate the company’s CE Mark-approved MagicTouch sirolimus-coated percutaneous transluminal angioplasty (PTA) balloon catheter for the treatment of peripheral artery disease (PAD).
EffPac Trial Confirms Benefit and Safety of Paclitaxel-Coated Balloon Catheter to Treat Intermittent Claudication
August 7, 2020—Jena University Hospital in Jena, Germany, announced the publication of results from the EffPac trial comparing balloon angioplasty with a paclitaxel-coated balloon (Luminor, iVascular) versus an uncoated balloon to treat vascular occlusion in the femoropopliteal region.
Concept Medical Completes Enrollment in SIRONA Trial of MagicTouch DCB
October 21, 2022—Concept Medical Inc. announced the completion of enrollment in the SIRONA randomized controlled trial (RCT), which is investigating percutaneous transluminal angioplasty (PTA) with the company’s MagicTouch sirolimus drug-coated balloon (DCB) versus paclitaxel DCBs for the treatment of peripheral artery disease (PAD) in the femoropopliteal vessel segment.
CE Mark Indication Expanded for CeloNova's Embozene Microspheres
January 14, 2015—CeloNova BioSciences, Inc. announced that it has received an expanded indication to its CE Mark approval in Europe for its Embozene embolic microspheres to include the treatment of benign prostatic hyperplasia.
